<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04800237</url>
  </required_header>
  <id_info>
    <org_study_id>VP-VQW-765-2201</org_study_id>
    <nct_id>NCT04800237</nct_id>
  </id_info>
  <brief_title>Evaluating the Effects of VQW-765 vs. Placebo in Performance Anxiety</brief_title>
  <official_title>A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Efficacy and Safety of VQW-765 in Patients With Performance Anxiety</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vanda Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Vanda Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multicenter, randomized, double-blind, placebo-controlled study to evaluate the&#xD;
      efficacy and safety of a single oral dose of VQW-765 compared to placebo in male and female&#xD;
      participants with performance anxiety.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 23, 2021</start_date>
  <completion_date type="Anticipated">October 2021</completion_date>
  <primary_completion_date type="Anticipated">October 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Subjective Units of Distress Scale (SUDS)</measure>
    <time_frame>1 Day</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinician Global Impression of Change (CGI-C) scale at visit 2</measure>
    <time_frame>1 Day</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Global Impression of Change (PGI-C) scale at visit 2</measure>
    <time_frame>1 Day</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of safety and tolerability of a single dose of VQW-765, as measured by spontaneous reporting of adverse events (AEs)</measure>
    <time_frame>1 Day</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">220</enrollment>
  <condition>Performance Anxiety</condition>
  <arm_group>
    <arm_group_label>VQW-765</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>VQW-765</intervention_name>
    <description>oral capsule</description>
    <arm_group_label>VQW-765</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>oral capsule</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Ability and willingness to provide written informed consent.&#xD;
&#xD;
          -  Sufficiently fluent in English to participate in the trial.&#xD;
&#xD;
          -  Male and female patients aged 18-70 years (inclusive).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Lifetime history of bipolar disorder, schizophrenia, psychosis, seizures, delusional&#xD;
             disorders or obsessive-compulsive disorder.&#xD;
&#xD;
          -  Current or planned pregnancy or nursing during the trial period.&#xD;
&#xD;
          -  A positive test for substances of abuse.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Vanda Pharmaceuticals, Inc.</last_name>
    <phone>202-734-3400</phone>
    <email>clinicaltrials@vandapharma.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Vanda Investigational Site</name>
      <address>
        <city>Garden Grove</city>
        <state>California</state>
        <zip>92845</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vanda Pharmaceuticals, Inc.</last_name>
      <phone>202-734-3400</phone>
      <email>clinicaltrials@vandapharma.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Vanda Investigational Site</name>
      <address>
        <city>San Jose</city>
        <state>California</state>
        <zip>95124</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vanda Pharmaceuticals, Inc.</last_name>
      <phone>202-734-3400</phone>
      <email>clinicaltrials@vandapharma.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Vanda Investigational Site</name>
      <address>
        <city>Torrance</city>
        <state>California</state>
        <zip>90502</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vanda Pharmaceuticals Inc.</last_name>
      <phone>202-734-3400</phone>
      <email>clinicaltrials@vandapharma.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Vanda Investigational Site</name>
      <address>
        <city>Berlin</city>
        <state>New Jersey</state>
        <zip>08009</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vanda Pharmaceuticals, Inc.</last_name>
      <phone>202-734-3403</phone>
      <email>clinicaltrials@vandapharma.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Vanda Investigational Site</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vanda Pharmaceuticals, Inc.</last_name>
      <phone>202-734-3400</phone>
      <email>clinicaltrials@vandapharma.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Vanda Investigational Site</name>
      <address>
        <city>Staten Island</city>
        <state>New York</state>
        <zip>10312</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vanda Pharmaceuticals, Inc.</last_name>
      <phone>202-734-3400</phone>
      <email>clinicaltrials@vandapharma.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Vanda Investigational Site</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45212</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vanda Pharmaceuticals, Inc.</last_name>
      <phone>202-734-3400</phone>
      <email>clinicaltrials@vandapharma.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Vanda Investigational Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77074</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vanda Pharmaceuticals, Inc.</last_name>
      <phone>202-734-3400</phone>
      <email>clinicaltrials@vandapharma.com</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>March 10, 2021</study_first_submitted>
  <study_first_submitted_qc>March 12, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 16, 2021</study_first_posted>
  <last_update_submitted>October 15, 2021</last_update_submitted>
  <last_update_submitted_qc>October 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>social phobia</keyword>
  <keyword>social anxiety disorder</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anxiety Disorders</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

